CN116514759A - 一种二氢杨梅素的合成方法 - Google Patents
一种二氢杨梅素的合成方法 Download PDFInfo
- Publication number
- CN116514759A CN116514759A CN202211523721.1A CN202211523721A CN116514759A CN 116514759 A CN116514759 A CN 116514759A CN 202211523721 A CN202211523721 A CN 202211523721A CN 116514759 A CN116514759 A CN 116514759A
- Authority
- CN
- China
- Prior art keywords
- methoxymethoxy
- tris
- phenyl
- tri
- dihydromyricetin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 title claims abstract description 64
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 238000001308 synthesis method Methods 0.000 title claims description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 28
- FBSFWRHWHYMIOG-UHFFFAOYSA-N methyl 3,4,5-trihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(O)=C1 FBSFWRHWHYMIOG-UHFFFAOYSA-N 0.000 claims abstract description 28
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000005882 aldol condensation reaction Methods 0.000 claims abstract description 5
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 5
- 230000002378 acidificating effect Effects 0.000 claims abstract description 4
- -1 3,4, 5-tris (methoxymethoxy) benzyl Chemical group 0.000 claims description 41
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- OOJVSLJUIUIZAR-UHFFFAOYSA-N 2-(methoxymethoxy)-1-phenylethanone Chemical compound COCOCC(=O)C1=CC=CC=C1 OOJVSLJUIUIZAR-UHFFFAOYSA-N 0.000 claims description 28
- 239000007983 Tris buffer Substances 0.000 claims description 20
- OHZUONDIUXNPNA-UHFFFAOYSA-N 3,4,5-tris(methoxymethoxy)benzaldehyde Chemical compound COCOC1=CC(C=O)=CC(OCOC)=C1OCOC OHZUONDIUXNPNA-UHFFFAOYSA-N 0.000 claims description 18
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 17
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 17
- JAMFGQBENKSWOF-UHFFFAOYSA-N bromo(methoxy)methane Chemical compound COCBr JAMFGQBENKSWOF-UHFFFAOYSA-N 0.000 claims description 15
- IVGXSUVFTLWJBF-UHFFFAOYSA-N methyl 3,4,5-tris(methoxymethoxy)benzoate Chemical compound COCOC=1C=C(C(=O)OC)C=C(C=1OCOC)OCOC IVGXSUVFTLWJBF-UHFFFAOYSA-N 0.000 claims description 13
- 238000003786 synthesis reaction Methods 0.000 claims description 13
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- XLEYFDVVXLMULC-UHFFFAOYSA-N 2',4',6'-trihydroxyacetophenone Chemical compound CC(=O)C1=C(O)C=C(O)C=C1O XLEYFDVVXLMULC-UHFFFAOYSA-N 0.000 claims description 6
- 238000006555 catalytic reaction Methods 0.000 claims description 6
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 5
- 238000005755 formation reaction Methods 0.000 claims description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 150000002978 peroxides Chemical class 0.000 claims description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 238000010189 synthetic method Methods 0.000 claims 2
- 238000000746 purification Methods 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 6
- CPEXFJVZFNYXGU-UHFFFAOYSA-N 2,4,6-trihydroxybenzophenone Chemical compound OC1=CC(O)=CC(O)=C1C(=O)C1=CC=CC=C1 CPEXFJVZFNYXGU-UHFFFAOYSA-N 0.000 abstract description 4
- 238000006735 epoxidation reaction Methods 0.000 abstract description 4
- 238000007142 ring opening reaction Methods 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 238000002425 crystallisation Methods 0.000 abstract description 3
- 230000008025 crystallization Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000003647 oxidation Effects 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 150000002148 esters Chemical class 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000012074 organic phase Substances 0.000 description 10
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 8
- 238000002329 infrared spectrum Methods 0.000 description 8
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 5
- 229940116852 myricetin Drugs 0.000 description 5
- 235000007743 myricetin Nutrition 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- RGZHEOWNTDJLAQ-UHFFFAOYSA-N 3,4,5-trihydroxybenzaldehyde Chemical compound OC1=CC(C=O)=CC(O)=C1O RGZHEOWNTDJLAQ-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- 241001018563 Nekemias grossedentata Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 241001122767 Theaceae Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- IBKQQKPQRYUGBJ-UHFFFAOYSA-N methyl gallate Natural products CC(=O)C1=CC(O)=C(O)C(O)=C1 IBKQQKPQRYUGBJ-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000563984 Ampelopsis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
- 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 101150112743 HSPA5 gene Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 101100111629 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR2 gene Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940045348 brown mixture Drugs 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 101150028578 grp78 gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002910 solid waste Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种外消旋体二氢杨梅素的合成方法,以3,4,5‑三羟基苯甲酸甲酯和2,4,6‑三羟基苯乙酮为原料,经酚羟基保护、酯还原氧化、Aldol缩合后环氧化,于酸性条件下开环与酚羟基成醚,反应结束后进行分离、纯化、结晶得到高纯度的二氢杨梅素。本方法具有高效、高产率、设备简单,生产程序绿色环保的特性,具有较高的经济效益以及社会效益。
Description
技术领域
本发明属于化学合成技术领域,具体涉及外消旋体二氢杨梅素的合成方法。
背景技术
二氢杨梅素,化学名为(2R,3R)-3,5,7-三羟基-2-(3,4,5-三羟基苯基)苯并二氢吡喃-4-酮,亦称双氢杨梅树皮素、白蔽素,是藤茶中含量最高的天然类黄酮,除了具有类黄酮一般特征外,它还具有保护心脏、神经、肝、肾的功能,亦有清除自由基、抗氧化、抗血栓、抗肿瘤之功效,亦用于治疗细菌感染,哮喘等疾病;还可解除醇中毒,预防酒精肝、脂肪肝,降低肝癌发病率的功效。在体外可靶向结合GRP78蛋白,显著降低细胞内油滴形成,具有抗糖尿病的潜力;能改变革兰氏阳性菌细胞膜通透性,且具有明显呼吸抑制作用,对于革兰氏阴性菌具有明显的呼吸抑制作用,是一种潜在的抗菌药物。
市售二氢杨梅素多从藤茶中提取,提取难度大,纯度低;也可以从杨梅素半合成得到。二氢杨梅素在葡萄科蛇葡萄属植物中含量最高,提取工艺一般以水、醇为溶剂,再经结晶可得纯度较高的二氢杨梅素。虽然二氢杨梅素在蛇葡萄藤中含量高,但其资源有限,产量受到蛇葡萄藤资源量限制,且其提取、分离、纯化所得收率并不高,且提取过程中能耗高、污染大,不利于进一步扩大市场需求。综上,传统方法存在着天然提取资源利用率不高,提取二氢杨梅素后影响其他活性成分的提取利用,造成成本大大提高;分离提纯过程中产生大量污染物,能耗大,难以得到高纯二氢杨梅素;而以杨梅素半合成工艺进行合成,其不仅需要进行天然杨梅素进行提取,还需对副产物进行分离处理,不适于工业化大规模生产;目前亦有从2-(3,4,5-三羟基)-苯丙烯酸酰氯起始全合成的专利申请(CN 103819442 A),但酰氯易于水解,对于储存的要求更高,对溶剂含水量有更加严格的要求,且其所用路易斯酸为三氯化铝,会产生大量的固体废物,并不适于作为工业化生产的原料;其采用间氯过氧苯甲酸进行缺电子烯烃环氧化,产生大量副产物间氯苯甲酸,原子利用率不高,其合成路线还可继续改进。大多数针对于二氢杨梅素的研究论文采用的合成方法多为从3,4,5-三羟基苯甲醛起始,经酚羟基保护后进行Aldol缩合,但3,4,5-三羟基苯甲醛价格高昂,且酚羟基保护条件苛刻,不易实现工业生产。
为解决上述问题,并进一步降低生产成本,本发明采用更短、更高产率、更环保的全合成路线,使用廉价的3,4,5-三羟基苯甲酸甲酯与2,4,6-三羟基苯乙酮为原料,对两个起始原料进行保护后经缩合、环氧化、酸性开环成醚,3步合成二氢杨梅素。该路线成本低、绿色环保、产率高,有较好的应用价值。其与上述方法不同之特征在于:采用新的起始原料3,4,5-三羟基苯甲酸甲酯以及2,4,6-苯乙酮,其余原辅料均为常规化工反应试剂,反应条件温和、安全,工艺更加绿色环保。对二氢杨梅素进行全合成具有杂质少,纯度高,含量高的优点,比天然提取的二氢杨梅素质量好,且合成路线短,设备简单,工艺简洁。相较于已有文献(a.J.Nat.Prod.,1989,52(5),1100;b.Bioorgan.Med.Chem.,2007,15,2396;c.Phytochemistry,70,1255),该方法在相同实验室条件下均有所改良,且替代了原有的具有强烈毒性与致癌性的保护剂甲氧基甲基氯。综上所述,本发明从经济、环境、职业健康角度均为优良工业化生产路线。
发明内容
为了解决上述问题,本发明提供了一种二氢杨梅素的合成方法,以3,4,5-三羟基苯甲酸甲酯以及2,4,6-三羟基苯乙酮为原料,经酚羟基保护、酯还原成醇再氧化为醛、Aldol缩合后进行双键环氧化,于酸性条件下开环与酚羟基成醚,反应结束后进行分离、纯化、结晶得到高纯度的二氢杨梅素。
为了实现上述目的,本发明采用以下技术方案:
(1)在N,N-二异丙基乙胺的催化下,3,4,5-三羟基苯甲酸甲酯与甲氧基甲基溴在四氢呋喃中反应生成3,4,5-三(甲氧基甲氧基)苯甲酸甲酯,3,4,5-三(甲氧基甲氧基)苯甲酸甲酯进一步被还原为3,4,5-三(甲氧基甲氧基)苯甲醇,再经氧化反应生成3,4,5-三(甲氧基甲氧基)苯甲醛;
(2)在N,N-二异丙基乙胺的催化下,2,4,6-三羟基苯乙酮与甲氧基甲基溴在二氯甲烷中反应生成2-羟基-4,6-二(甲氧基甲氧基)苯乙酮,进一步在四氢呋喃中以NaH作碱继续与甲氧基甲基溴反应生成2,4,6-三(甲氧基甲氧基)-苯乙酮;
(3)3,4,5-三(甲氧基甲氧基)苯甲醛与2,4,6-三(甲氧基甲氧基)-苯乙酮溶于乙醇中,在碱的催化下进行Aldol缩合反应,生成1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮;
(4)1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮与过氧化物反应生成1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮;
(5)将1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮溶于甲醇,在氮气保护下,在酸性条件下脱保护与酚羟基开环成醚,生成外消旋体二氢杨梅素
优选地,所述步骤(1)中,3,4,5-三羟基苯甲酸甲酯与甲氧基甲基溴的反应温度为-5℃-0℃;3,4,5-三羟基苯甲酸甲酯的还原剂为氢化铝锂;3,4,5-三(甲氧基甲氧基)苯甲醇的氧化剂为二氧化锰。
优选地,所述步骤(2)中的反应温度为-5-0℃。
优选地,所述步骤步骤(3)中的碱为氢氧化钾,步骤(4)中的过氧化物为过氧化氢或间氯过氧苯甲酸,步骤(3)和(4)中的反应温度为25℃-30℃。
优选地,所述步骤(5)中,成醚反应选用的是盐酸,反应温度控制在40-45℃。
附图说明
图1为二氢杨梅素合成路线。
图2为3,4,5-三(甲氧基甲氧基)苯甲酸甲酯(2)1H NMR谱图。
图3为3,4,5-三(甲氧基甲氧基)苯甲酸甲酯(2)13C NMR谱图。
图4为3,4,5-三(甲氧基甲氧基)苯甲醇(3)1H NMR谱图。
图5为3,4,5-三(甲氧基甲氧基)苯甲醇(3)13C NMR谱图。
图6为3,4,5-三(甲氧基甲氧基)苯甲醛(4)1H NMR谱图。
图7为3,4,5-三(甲氧基甲氧基)苯甲醛(4)13C NMR谱图。
图8为2-羟基-4,6-二(甲氧基甲氧基)苯乙酮(6)1H NMR谱图。
图9为2-羟基-4,6-二(甲氧基甲氧基)苯乙酮(6)13C NMR谱图。
图10为2,4,6-三(甲氧基甲氧基)苯乙酮(7)1H NMR谱图。
图11为2,4,6-三(甲氧基甲氧基)苯乙酮(7)13C NMR谱图。
图12为1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8)1H NMR谱图。
图13为1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8)13C NMR谱图。
图14为1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮(9)1H NMR谱图。
图15为1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮(9)13C NMR谱图。
图16为二氢杨梅素1H NMR谱图。
图17为二氢杨梅素13C NMR谱图。
图18为3,4,5-三(甲氧基甲氧基)苯甲酸甲酯(2)IR谱图。
图19为3,4,5-三(甲氧基甲氧基)苯甲醇(3)IR谱图。
图20为3,4,5-三(甲氧基甲氧基)苯甲醛(4)IR谱图。
图21为2-羟基-4,6-二(甲氧基甲氧基)苯乙酮(6)IR谱图。
图22为2,4,6-三(甲氧基甲氧基)苯乙酮(7)IR谱图。
图23为1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8)IR谱图。
图24为1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮(9)IR谱图。
图25为二氢杨梅素IR谱图。
具体实施方式
实施例1 3,4,5-三(甲氧基甲氧基)苯甲醛(4)的大量合成
取5g(1eq)没食子酸甲酯(1)溶于150mL四氢呋喃(THF)中,冰水浴搅拌下加入甲氧基甲基溴(MOMBr)(14.5mL(6eq)in 20mL THF)和N,N-二异丙基乙胺(DIPEA,31mL(6eq)),反应恢复至室温搅拌24小时,直至薄层层析(TLC)显示反应完全。反应液倾入500mL水中,用二氯甲烷(DCM)(200mL×2)萃取,合并有机相,水洗,干燥脱除溶剂得无色油,为3,4,5-三(甲氧基甲氧基)苯甲酸甲酯(2)。取前述无色油溶于20mL无水THF,冰水浴搅拌下逐滴加入含1.7g(1.5eq)四氢铝锂(LAH)的100mL THF中,滴加完毕后恢复至室温,搅拌24小时,冰水浴搅拌下加水猝灭反应,以硅藻土作助滤剂抽滤,滤液用100mL水与100mL×2乙酸乙酯(EA)萃取,合并有机相,水洗干燥,脱除溶剂得到淡黄色油状物,为3,4,5-三(甲氧基甲氧基)苯甲醇(3)。将前述油状物溶于150mL DCM,加入13g(5eq)活性MnO2,搅拌24小时,抽滤,脱去溶剂,得到灰白固体7g(4),即3,4,5-三(甲氧基甲氧基)苯甲醛。
实施例2 3,4,5-三(甲氧基甲氧基)苯甲醛(4)的实验室合成
取0.5g(1eq)没食子酸甲酯(1)溶于15mL无水THF中,冰浴搅拌下加入MOMBr(6eq,2.02g in 20mL THF)与DIPEA(6eq,2.10g),反应恢复至室温后,搅拌12小时。反应液以20mL水与20mL×2DCM萃取,以水多次洗涤有机相,脱去溶剂后得到无色油状液体(2),为3,4,5-三(甲氧基甲氧基)苯甲酸甲酯(2)。柱层析纯化得纯品(PE:EA=2:1),实际制备过程中不经纯化。
如图2所示,1H NMR(600MHz,Chloroform-d)δ7.45(s,2H),5.16(s,4H),5.13(s,2H),3.80(s,3H),3.53(s,3H),3.43(s,6H)。
如图3所示,13CNMR(150MHz,Chloroform-d)δ165.32,149.66,139.63,124.87,110.52,97.46,94.21,56.19,55.36,51.20。
前述无色油(2)溶于20mL无水THF,冰浴搅拌下逐滴加入含LAH(1.5eq,0.15g)的10mL THF中,滴加完毕后恢复至室温,待TLC检测反应完全,冰浴搅拌下逐滴滴加水,猝灭反应,以硅藻土作助滤剂抽滤,滤液用20mL水与乙酸乙酯(20mL×2)萃取两次,合并有机相,水洗,有机相以无水硫酸钠干燥,脱去溶剂,得到淡黄色油状物(3),为3,4,5-三(甲氧基甲氧基)苯甲醇。柱层析纯化(PE:EA=1:2)得纯品并做核磁检测,实际制备过程中不经纯化。
如图4所示,1H NMR(600MHz,Chloroform-d)δ6.78(s,2H),5.13(s,4H),5.06(s,2H),4.51(s,2H),3.54(s,3H),3.43(s,6H),1.88(s,1H)。
如图5所示,13C NMR(150MHz,Chloroform-d)δ165.32,149.66,139.63,124.87,110.52,97.46,94.21,56.19,55.36,51.20。
将前述淡黄色油状物(3)溶于15mL DCM中,加入5eq活性MnO2,TLC检测反应直至反应完全,抽滤,脱去溶剂。柱层析纯化(PE:EA=3:1),得到淡黄色油状物0.37g,静置片刻后结晶为白色固体(4),即3,4,5-三(甲氧基甲氧基)苯甲醛。前述3步总收率48.2%。
如图6所示,1H NMR(600MHz,Chloroform-d)δ9.78(s,1H),7.32(s,2H),5.20(s,4H),5.17(s,2H),3.55(s,3H),3.45(s,6H)。
如图7所示,13C NMR(150MHz,Chloroform-d)δ189.86,150.46,140.85,131.37,110.30,97.48,94.22,56.25,55.39。
实施例3 2,4,6-三(甲氧基甲氧基)苯乙酮(7)的大量合成
取2,4,6-三羟基苯乙酮(5)5g于两颈烧瓶中,加入160mL干燥DCM,冰浴下加入15mLDIPEA,将7mL甲氧基甲基溴溶于10mL DCM中逐滴加入,TLC监测至反应完全,约5-10分钟完成反应。以饱和碳酸氢钠溶液洗涤有机相(200mL×1),再以饱和浓盐水洗涤(200mL×2),得到8.5g黄色油状物(6),为2-羟基-4,6-二(甲氧基甲氧基)苯乙酮。取1.8g NaH(60%分散于矿物油中)于二颈圆底烧瓶中,加入100mL超干THF,冰水浴搅拌,待溶液稳定后滴入前述黄色油状物的THF溶液,滴加完毕后,将4.8mL MOMBr溶于10mL THF中逐滴滴入,冰浴搅拌1小时。反应以水猝灭,饱和盐水萃取,收集有机相。干燥脱除溶剂后得黄色油状液体8.9g(7),为2,4,6-三(甲氧基甲氧基)苯乙酮。
实施例4 2,4,6-三(甲氧基甲氧基)苯乙酮(7)的实验室合成
取2,4,6-三羟基苯乙酮(5)1g于两颈烧瓶中,加入50mL干燥DCM,冰浴下加入5.2mLDIPEA,搅拌十分钟后,滴加4mL甲氧基甲基溴,零度搅拌5~10分钟。以饱和碳酸氢钠溶液洗涤有机相(20mL×1),再以饱和浓盐水洗涤(20mL×2)。柱层析(EA:PE=1:3),收白色油状液体1.3975g,放置一段时间后凝固为白色固体(6),为2-羟基-4,6-二(甲氧基甲氧基)苯乙酮,收率89%。
如图8所示,1H NMR(600MHz,Chloroform-d)δ13.64(s,1H),6.19(d,J=2.4Hz,1H),6.17(d,J=2.4Hz,1H),5.18(s,2H),5.10(s,2H),3.45(s,3H),3.40(s,3H),2.58(s,3H)。
如图9所示,13C NMR(150MHz,Chloroform-d)δ202.20,165.82,162.44,159.35,105.92,96.14,93.47,93.00,55.69,55.43,31.99。
取0.7g NaH(60%dispersion in mineral oil)于两颈烧瓶中,加入20mL超干THF,冰浴搅拌,待溶液稳定后加入1g前述白色固体(6),加入1mL甲氧基甲基溴,冰浴搅拌一小时。反应以水猝灭,饱和盐水萃取,收集有机相。柱层析(EA:PE=1:3),收白色油状液体(7)1.09g,为2,4,6-三(甲氧基甲氧基)苯乙酮,收率92%。
如图10所示,1H NMR(600MHz,Chloroform-d)δ6.44(s,2H),5.08(d,J=0.9Hz,2H),5.07(d,J=0.8Hz,4H),3.40(d,J=0.9Hz,3H),3.39(d,J=0.9Hz,6H),2.43(d,J=0.9Hz,3H)。
如图11所示,13C NMR(150MHz,Chloroform-d)δ200.51,158.45,154.18,115.88,96.07,93.74,93.44,55.33,55.22,31.54。
实施例5 1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8)的大量合成
将前述两例中所合成的3,4,5-三(甲氧基甲氧基)苯甲醛(4)、2,4,6-三(甲氧基甲氧基)苯乙酮(7)溶于150mL乙醇混匀,搅拌下加入3.4g KOH(2eq),30℃搅拌24小时,反应液倾入十倍体积冰水中搅拌30分钟,抽滤。沉淀以500mL石油醚洗涤,随后以乙酸乙酯溶解沉淀,溶液经干燥后减压除去,得黄色固体1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8)10.4g。
实施例6 1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8)的实验室合成
取3,4,5-三(甲氧基甲氧基)苯甲醛(4)0.4970g,2,4,6-三(甲氧基甲氧基)苯乙酮(7)0.5120g于两颈烧瓶中,加入20mL干燥乙醇,搅拌下加入0.1975g KOH(2eq),30℃搅拌6小时,柱层析(EA:PE=1:2,后改为1:1)得0.90g黄色油状液体,放置后凝固为黄色固体1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8),收率91%。
如图12所示,1H NMR(600MHz,Chloroform-d)δ7.15(d,J=16.0Hz,1H),6.98(s,2H),6.82(d,J=16.0Hz,1H),6.50(s,2H),5.14(s,4H),5.13(s,2H),5.11(s,2H),5.05(s,4H),3.54(s,3H),3.45(s,3H),3.42(s,6H),3.32(s,6H)。
如图13所示,13C NMR(150MHz,Chloroform-d)δ193.28,158.62,154.75,150.27,143.83,137.36,129.96,127.88,113.56,109.29,97.48,96.04,94.27,93.55,93.49,56.18,55.30,55.27。
实施例7 1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮(9)的大量合成
取2g 1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8)于单口烧瓶中,加入0.28g氢氧化钠,25mL甲醇,待固体于搅拌下溶解后,加入3.6mL过氧化氢(30%水溶液),室温搅拌12小时。反应液以100mL×2乙酸乙酯和水萃取,合并有机相,以无水硫酸钠干燥,真空干燥溶剂得1.9g白色晶体1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮(9),定量转化。
实施例8 1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮(9)的实验室合成
取0.5g 1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮(8)于单口烧瓶中,加入0.07g氢氧化钠,10mL甲醇,待固体于搅拌下溶解后,加入0.9mL过氧化氢(30%水溶液),室温搅拌12小时。反应液以50mL×2乙酸乙酯和水萃取,合并有机相,以无水硫酸钠干燥,真空干燥溶剂得0.49g白色晶体1-(2,4,6-三(甲氧基甲氧基))苯基)-3-(3,4,5-三(甲氧基甲氧基))苯基环氧乙烷-2-基)甲酮(9),定量转化。
如图14所示,1H NMR(600MHz,Chloroform-d)δ6.72(s,2H),6.45(s,2H),5.12-5.03(m,12H),3.86(d,J=1.8Hz,1H),3.79(d,J=1.8Hz,1H),3.53(s,3H),3.40(d,J=4.6Hz,9H),3.32(s,6H)。
如图15所示,13C NMR(150MHz,Chloroform-d)δ194.93,159.86,155.98,150.29,135.67,131.38,111.60,106.47,97.49,95.88,94.17,93.81,93.36,63.23,58.39,56.14,55.34,55.31,55.24。
实施例9外消旋二氢杨梅素(10)的大量制备
取1.9g 1-(2,4,6-三(甲氧基甲氧基)苯基)-3-(3,4,5-三(甲氧基甲氧基)苯基环氧乙烷-2-基)甲酮(9)溶于9mL甲醇,在氮气保护下加入11mL 1.8mol/L氯化氢的甲醇溶液,于45℃下搅拌45分钟,将溶剂旋干,再用水泵抽气10分钟以尽可能去除氯化氢气体。以特定体积分数的乙醇-水溶液重结晶三次,得到较纯外消旋二氢杨梅素0.32g。
实施例10外消旋体二氢杨梅素(10)的实验室合成
取实施例8中所得1-(2,4,6-三(甲氧基甲氧基)苯基)-3-(3,4,5-三(甲氧基甲氧基)苯基环氧乙烷-2-基)甲酮(9)溶于5mL甲醇,在氮气保护下加入2.5mL 3mol/L氯化氢的甲醇溶液,于45℃下搅拌45分钟,将溶剂旋干,再用泵抽气数分钟以尽可能去除氯化氢气体。将得到的褐色混合物以二氯甲烷与甲醇的混合液(v/v=10:1)50mL溶解,加适量硅胶制样,以柱层析纯化(DCM:甲醇=20:1),得到类白色固体0.20g,为外消旋二氢杨梅素(10),总收率70%。
如图16所示,1H NMR(600MHz,DMSO-d6)δ11.89(s,1H),10.81(s,1H),8.89(s,2H),8.21(s,1H),6.39(s,2H),5.90(d,J=2.1Hz,1H),5.85(d,J=2.1Hz,1H),5.75(d,J=6.2Hz,1H),4.90(d,J=10.8Hz,1H),4.41(dd,J=10.9,6.1Hz,1H)。
如图17所示,13C NMR(150MHz,DMSO-d6)δ198.03,167.41,163.80,162.97,146.15,133.91,127.58,107.40,100.88,96.43,95.45,83.69,72.09。
HRMS m/z[M+H]+321.0596(calcd.C15H12O8,321.0605)。
Claims (5)
1.二氢杨梅素的合成方法,其特征在于,包括以下步骤:
(1)在N,N-二异丙基乙胺的催化下,3,4,5-三羟基苯甲酸甲酯与甲氧基甲基溴在四氢呋喃中反应生成3,4,5-三(甲氧基甲氧基)苯甲酸甲酯,3,4,5-三(甲氧基甲氧基)苯甲酸甲酯进一步被还原为3,4,5-三(甲氧基甲氧基)苯甲醇,再经氧化反应生成3,4,5-三(甲氧基甲氧基)苯甲醛;
(2)在N,N-二异丙基乙胺的催化下,2,4,6-三羟基苯乙酮与甲氧基甲基溴在二氯甲烷中反应生成2-羟基-4,6-二(甲氧基甲氧基)苯乙酮,进一步在四氢呋喃中以NaH作碱继续与甲氧基甲基溴反应生成2,4,6-三(甲氧基甲氧基)-苯乙酮;
(3)3,4,5-三(甲氧基甲氧基)苯甲醛与2,4,6-三(甲氧基甲氧基)-苯乙酮溶于乙醇中,在碱的催化下进行Aldol缩合反应,生成1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮;
(4)1-(2,4,6)-三(甲氧基甲氧基)苯基-3-(3,4,5-三(甲氧基甲氧基)苯基)丙-2-烯-1-酮与过氧化物反应生成1-(2,4,6-三(甲氧基甲氧基)苯基)-3-(3,4,5-三(甲氧基甲氧基)苯基环氧乙烷-2-基)甲酮;
(5)将1-(2,4,6-三(甲氧基甲氧基)苯基)-3-(3,4,5-三(甲氧基甲氧基)苯基环氧乙烷-2-基)甲酮溶于甲醇,在氮气保护下,在酸性条件下脱保护与酚羟基开环成醚,生成外消旋体二氢杨梅素;
2.根据权利要求1所述的合成方法,其特征在于,所述步骤(1)中,3,4,5-三羟基苯甲酸甲酯与甲氧基甲基溴的反应温度为-5℃-0℃;3,4,5-三羟基苯甲酸甲酯的还原剂为氢化铝锂;3,4,5-三(甲氧基甲氧基)苯甲醇的氧化剂为二氧化锰。
3.根据权利要求1所述的合成方法,其特征在于,所述步骤(2)中的反应温度为-5-0℃。
4.根据权利要求1所述的合成方法,其特征在于,所述步骤(3)中的碱为氢氧化钾,步骤(4)中的过氧化物为过氧化氢或间氯过氧苯甲酸,步骤(3)和(4)中的反应温度为25-30℃。
5.根据权利要求1所述的合成方法,其特征在于,所述步骤(5)中,成醚反应选用的是盐酸,反应温度控制在40-45℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211523721.1A CN116514759A (zh) | 2022-11-25 | 2022-11-25 | 一种二氢杨梅素的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211523721.1A CN116514759A (zh) | 2022-11-25 | 2022-11-25 | 一种二氢杨梅素的合成方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116514759A true CN116514759A (zh) | 2023-08-01 |
Family
ID=87392718
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211523721.1A Pending CN116514759A (zh) | 2022-11-25 | 2022-11-25 | 一种二氢杨梅素的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116514759A (zh) |
-
2022
- 2022-11-25 CN CN202211523721.1A patent/CN116514759A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2668176B1 (en) | A novel process for synthesis of polyphenols | |
CN102630226A (zh) | 恩替卡韦的合成方法及其中间体化合物 | |
CN112608296A (zh) | 巴西苏木素类天然产物Brazilane的合成方法 | |
US6288242B1 (en) | Processes and intermediates for preparing substituted chromanol derivatives | |
US20070037874A1 (en) | Manufacturing process of isoflavan or isoflavene derivatives | |
US20140200355A1 (en) | Method for Preparing Optically Pure (-)-Clausenamide Compound | |
CN102344431B (zh) | 一种制备奈必洛尔盐酸盐的方法 | |
CN109053496B (zh) | 一种3-Boc-氨甲基环丁酮的合成方法 | |
CN116514759A (zh) | 一种二氢杨梅素的合成方法 | |
CN110713477A (zh) | 鲁比前列酮(lubiprostone)的制备方法和其中间物 | |
CN112047815B (zh) | 一种大麻二酚类化合物的制备方法 | |
CN112479967B (zh) | 胆绿素类化合物及其制备方法和用途 | |
CN107954966B (zh) | 一种Sc(III)催化合成2,3-二取代-4H-苯并吡喃的制备方法 | |
CN108727323B (zh) | 一种氮杂环卡宾催化合成三氟甲基取代高异黄酮类化合物的方法 | |
JP4540197B2 (ja) | (e)−3−メチル−2−シクロペンタデセノンの製造法 | |
CN115322106B (zh) | 反式-3-叠氮-1-甲基环丁醇和反式-3-氨基-1-甲基环丁醇的合成方法 | |
AU2021380304B2 (en) | Preparation method for cannflavin compounds | |
CN103113338B (zh) | Tanikolide的不对称全合成方法 | |
KR101122397B1 (ko) | Ailanthoidol의 경제적 합성 | |
KR100966027B1 (ko) | 데커신 및 데커신 유사체의 신규한 제조방법 | |
RU2486191C1 (ru) | Способ получения 1,2-бис(гидроксиметил)-о-карборана | |
CN106588850B (zh) | 一种TalienbisflavanA的全合成方法 | |
CN107118189A (zh) | 一种前列腺素合成中间体的制备方法 | |
CN105481814A (zh) | 一种异鼠李素的合成方法 | |
CN118164833A (zh) | 一种芳香丁酮类化合物的合成方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |